Axsome Therapeutics Reports Impressive Growth in Q3 2025
NEW YORK, -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a leading biopharmaceutical company, has just announced remarkable financial results for the third quarter of 2025. The company's net product revenue reached an impressive $171.0 million, marking a significant 63% growth compared to the same quarter in the previous year.
Total Revenue Breakdown
Axsome's strong performance can be attributed to the robust contributions from all three of its marketed products. Notably, AUVELITY generated net product sales of $136.1 million, showcasing a 69% increase compared to Q3 of 2024. Meanwhile, SUNOSI reported net product revenue of $32.8 million, reflecting a 35% year-over-year growth. Additionally, SYMBRAVO, which was newly launched in June 2025, brought in net product sales of $2.1 million for the quarter.
Significant Pipeline Developments
Axsome continues to make strides with its expansive development pipeline. Recently, the company submitted a supplemental New Drug Application (sNDA) for AXS-05 aimed at treating agitation in Alzheimer’s disease. This condition is highly prevalent and presents a critical unmet medical need for millions of patients in the U.S.
CEO Insights
During the announcement, Dr. Herriot Tabuteau, CEO of Axsome Therapeutics, expressed optimism about the company's growth trajectory. He stated, "Our broad development pipeline continues to advance, and we are well-positioned to deliver transformative new medicines for patients living with serious CNS disorders."
Diving Deeper into Financial Performance
Financially, Axsome's total net product revenue for the third quarter of 2024 was $104.8 million, indicating strong year-over-year growth. For the FY 2025, AUVELITY's sales have shown considerable sequential growth as well, pointing to effective commercialization strategies.
Cost and Expenses
On the expense side, Axsome reported total costs of revenue amounting to $11.9 million, compared to $8.4 million during the same period last year. Research and development expenses totaled $40.2 million, down from $45.4 million in 2024 due to completed trials. However, selling, general, and administrative expenses rose to $150.2 million, significantly compared to $95.6 million in the prior year, reflecting intensifying marketing efforts.
Financial Guidance
Moving forward, Axsome believes its existing cash reserves are adequate to support operations until the company achieves cash flow positivity. The firm aims to build on its expanding revenue base and pipeline progress as it navigates the evolving biopharmaceutical landscape.
Commercial Highlights
About AUVELITY, which is the first rapid-acting oral NMDA receptor antagonist and sigma-1 receptor agonist, approximately 209,000 prescriptions were written in Q3 2025, representing a 46% year-over-year increase. Payer coverage for AUVELITY now stands at about 85% across various channels.
Future Pipeline and Trials
Axsome is advancing several innovative product candidates targeted at serious psychiatric conditions. Key anticipated milestones include NDA submissions for AXS-12 for narcolepsy and Phase 2/3 trials for AXS-05 in smoking cessation. Moving into 2026, significant trial results are expected for its other products in the pipeline.
Conference Call Details
The company hosted a conference call to discuss these results, allowing stakeholders to gain insights into its strategy and future outlook. Axsome intends to keep the momentum going as it addresses the healthcare needs of individuals struggling with CNS disorders.
Frequently Asked Questions
What were Axsome's total revenues for Q3 2025?
Axsome Therapeutics reported total net product revenue of $171.0 million for Q3 2025.
How much did AUVELITY generate in sales?
AUVELITY generated net product sales of $136.1 million in Q3 2025, a 69% increase from the previous year.
What is the significance of AXS-05 in Axsome's pipeline?
AXS-05 targets agitation in Alzheimer's disease and has a supplemental NDA submitted to the FDA, addressing an unmet medical need.
What are Axsome's expectations for cash flow?
Axsome believes its current cash is sufficient to support operations until achieving cash flow positivity.
When will Axsome report trial results for its pipeline products?
Key trial results are anticipated in 2026 for various products, including those targeting narcolepsy and smoking cessation.
